A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis
about
Compstatin: a complement inhibitor on its way to clinical applicationIn vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-diseaseInfections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyDynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometryComplement in glomerular injury.Improving therapeutic efficacy of a complement receptor by structure-based affinity maturation.The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in miceNardilysin-dependent proteolysis of cell-associated VTCN1 (B7-H4) marks type 1 diabetes development.The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages.Complement-targeted therapeuticsEfficient osteoclast differentiation requires local complement activation.Molecular characterization and expression analysis of VSIG4 from the Asian yellow pond turtle, Mauremys mutica.Vav/Phospholipase Cgamma2-mediated control of a neutrophil-dependent murine model of rheumatoid arthritis.Regulation of CRIg expression and phagocytosis in human macrophages by arachidonate, dexamethasone, and cytokinesEarly window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imagingDeficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIgDiscrimination between host and pathogens by the complement system.CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites.Extracellular stimulation of VSIG4/complement receptor Ig suppresses intracellular bacterial infection by inducing autophagy.Breaking old paradigms: Th17 cells in autoimmune arthritis.Lessons from animal models of arthritis over the past decade.The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease.The complement system as a potential therapeutic target in rheumatic disease.Complement Receptors in Myeloid Cell Adhesion and Phagocytosis.CRIg signals induce anti-intracellular bacterial phagosome activity in a chloride intracellular channel 3-dependent manner.Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis.VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism.Profiling the enzymatic properties and inhibition of human complement factor B.Inhibition of Macrophage Complement Receptor CRIg by TRIM72 Polarizes Innate Immunity of the Lung.
P2860
Q24658454-D20B5EE5-4389-435A-BA32-905DC3794C53Q27307168-DFA5FA67-B4AF-4CF0-A089-9707C5A94FEAQ28972389-4665045E-5862-4485-A777-B293E1C8DED9Q33331674-172A1896-B7E5-494E-A28C-4C47EE09CEA2Q33376840-3B0F2611-41DD-4C71-8A2A-503633CD0D29Q33510862-25E7B0C8-7D34-4524-BCBF-C0FD313BAA79Q33685823-4AA14BEA-C5C4-4125-BA1E-97447CB6D7DEQ33687307-3745FF99-3171-4CC7-99C0-2D2524B126D8Q34227834-405ACFDD-808A-4A92-BBE2-6BA5953CF760Q34238386-25860211-AB82-41D0-81DD-35DE43666332Q34255011-CCB5DCD7-6CD3-43FF-B3DD-E56478EA9C7FQ34374041-DAF8832D-B416-43F3-A118-CD0B733B5C3BQ34418286-28021B15-A390-40CC-9F7D-1CCF9543A3EEQ34419714-25694B6C-AF68-4912-9E74-BA806E7BBBB5Q35167899-0D8A47A8-6679-40DF-8EC3-E93E7B2BEF0EQ35842735-8949DC25-0C51-46A3-B93F-583B34CC0F79Q36835163-A1AC657C-0D25-40F5-8D2C-AEA4D68BA9CCQ37170042-C441E699-A0C9-430C-BEBD-4D27414B0EBEQ37277340-F79FA03D-3A39-40BC-94C5-3FE1C93B877EQ37371571-681887AB-E78D-4441-8FE3-6894B135F094Q37464427-EBA5969C-E505-44A7-A705-5B530BF1C54BQ37619719-C122B983-F692-4EE8-A540-466F4F7E07D8Q37646847-F35F1C33-DEC4-43BD-BABE-D8F9DA08B6CAQ38631542-1D25FAF7-3861-4C5A-81D6-9EC276E8B58AQ38997578-848E7272-9BF9-4FEC-B7A4-747B0311381BQ39218085-6BDA4CF3-50E8-4936-B131-C23927345B3BQ42921553-CEDC11AA-F694-4376-B927-62E39A276D3FQ46267431-0D0A791F-37E0-4051-911D-AE152AF1AC14Q46962394-C3AD4EC2-64A6-4D8A-8471-C48069450827Q47264775-3BEB97F9-BF5B-4E17-BD6F-1CF62BA03BA8
P2860
A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A novel inhibitor of the alter ...... tion in experimental arthritis
@ast
A novel inhibitor of the alter ...... tion in experimental arthritis
@en
A novel inhibitor of the alter ...... tion in experimental arthritis
@nl
type
label
A novel inhibitor of the alter ...... tion in experimental arthritis
@ast
A novel inhibitor of the alter ...... tion in experimental arthritis
@en
A novel inhibitor of the alter ...... tion in experimental arthritis
@nl
prefLabel
A novel inhibitor of the alter ...... tion in experimental arthritis
@ast
A novel inhibitor of the alter ...... tion in experimental arthritis
@en
A novel inhibitor of the alter ...... tion in experimental arthritis
@nl
P2093
P2860
P50
P356
P1476
A novel inhibitor of the alter ...... tion in experimental arthritis
@en
P2093
Christian Wiesmann
Hongkang Xi
Jianping Yin
Kai H Barck
Karim Y Helmy
Kenneth J Katschke
Linda Rangell
Peter Gribling
Philip E Hass
Richard A D Carano
P2860
P304
P356
10.1084/JEM.20070432
P407
P577
2007-06-11T00:00:00Z